Latest News

 

 

 

Institute HEALTH celebrates GLP recertification

We are pleased to announce that JOANNEUM Research HEALTH has successfully renewed the GLP certification for its analytical laboratory, strengthening its positioning as a competent and professional partner for the pharmaceutical industry. Our analytical laboratory develops analytical methods in the research areas of bioanalytics and metabolomics and combines scientific competence with GLP/GCP standards for both complex research projects and drug development programs. We focus on the high quality of analytical results that are both traceable and tailored to the needs of our customers.

Download: GLP Certificate

Follow Up: Webinar - Informed decisions in dermal drug development with dOFM

We are pleased to announce that we have prepared some useful content from our Webinar "Informed decisions in dermal drug development with dOFM". Please find below a collection of valuable insights, a comprehensive Q&A Catalogue and easy access to all relevant resources. Browse through a collection of questions raised by our listeners during the live webinar to see which topics are particularly relevant for our audience. Take a more detailed look at the slides and download the presentation including some additional notes from our dOFM experts.

Live Recording

Presentation Slides

Speaker Notes

Q&A Catalogue

Study results on a short-acting Insulin published

Credit: JOANNEUM RESEARCH

In a cooperative contract research project, HEALTH and Med Uni Graz have tested a new insulin in a clinical phase 1 study on behalf of Arecor. The study, in which HEALTH was responsible for insulin analysis, statistical evaluation, clinical data management, and quality management, showed that the new insulin enters the bloodstream more quickly and thus also acts faster. As a result, blood glucose control in type 1 diabetics is optimized and dangerous hyper- and hypoglycemia can be avoided. The study results are now published in the top-ranking Journal Diabetes Care.

This new type of fast-acting insulin is an important step in the development of an artificial pancreas. HEALTH is proud to support our clients with new developments to further improve the lives of people with diabetes.

 

Webinar - Informed decisions in dermal drug development with dOFM

Dr Thomas Birngruber and Dr Frank Sinner will present valuable insights on improved formulation screening and local dermal PK and PD using dOFM sampling. This webinar will give you a concise overview of dOFM capabilities and introduce possible setups for preclinical and clinical studies. We will present several case studies for drug development, biomarker discovery and bioequivalence assessment. More information

Our experts will answer all your questions personally, such as:

  • How can dOFM improve your dermal drug development?
  • How to monitor local drug concentration in the dermis?
  • How to perform a head to head comparison of formulations in the same subject?
  • How to translate preclinical results directly into the clinical situation?

 

Contact Us

 

HEALTH – Institute for
Biomedicine and Health Sciences

Neue Stiftingtalstrasse 2/Entrance A/Third Floor
8010 Graz

Phone: +43 316 876-4000
Fax: +43 316 8769-4000

croservices@joanneum.at